Skip to search.
 TSX Down 1.14% TSX Ventures Down 1.33%

Celgene Corporation (CELG)

-NasdaqGS
103.22 Down 1.75(1.67%) May 3, 4:00PM EDT
Prev Close:104.97
Open:103.49
Bid:103.01 x 100
Ask:103.49 x 400
1y Target Est:136.82
Beta:1.61199
Earnings Date:Jul 21 - Jul 25 (Est.)
Day's Range:102.54 - 104.65
52wk Range:92.98 - 140.72
Volume:3,636,616
Avg Vol (3m):5,468,410
Market Cap:79.95B
P/E (ttm):53.21
EPS (ttm):1.94
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in USD.

Comparison

Symbol% ChgMkt Cap
CELGDown 1.67%79.95B
JNJDown 0.05%310.84B

Key Statistics

Forward P/E (1 yr):14.68
P/S (ttm):8.86
Ex-Dividend Date:N/A

Analysts

Annual EPS Est (Dec-16) :5.69
Quarterly EPS Est (Jun-16) :1.39
Mean Recommendation*:1.8
PEG Ratio (5 yr expected):0.82

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell ly... View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback